Positive outcomes could strengthen Arcturus Therapeutics Holdings Inc.’s ... If you are looking for an AI stock that is more promising than ARCT but that trades at less than 5 times its earnings ...

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...

While Arcturus Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key ...

Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday ...

Arcturus Therapeutics Holdings Inc. ARCT announced ... NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc ... reward growth stocks to buy we used the Finviz stock screener, Yahoo Finance, CNN, and Seeking ...

Arcturus Therapeutics Holdings Inc. (NASDAQ ... Analyst Myles Minter from William Blair maintained a Buy rating on the stock. Minter anticipates that the Phase II trial results for ARCT-032 ...